share_log

Wedbush Maintains Outperform on Astria Therapeutics, Raises Price Target to $22

Moomoo 24/7 ·  Mar 26 09:34

Wedbush analyst Laura Chico maintains Astria Therapeutics (NASDAQ:ATXS) with a Outperform and raises the price target from $17 to $22.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment